Host-acting compounds are emerging as potential alternatives to combating antibiotic
resistance. Here, we show that bosutinib, an FDA-approved chemotherapeutic for treating …

Infections caused by drug-resistant bacteria are a serious threat to public health worldwide,
and the discovery of novel antibacterial compounds is urgently needed. Here, we screened …

Pro-survival molecules including BCL-2 play critical roles in leukemia transformation and
chemoresistance. ABT-199/GDC-0199 (venetoclax) is an orally available BH3-mimetic that …

Venetoclax, the first-generation inhibitor of the apoptosis regulator B-cell lymphoma 2
(BCL2), disrupts the interaction between BCL2 and proapoptotic proteins, promoting the …

B‐cell lymphoma 2 (BCL‐2), a crucial member of the anti‐apoptotic BCL‐2 family, is
frequently dysregulated in cancer and plays an important role in acute myeloid leukemia …

Background The survival rate for acute myeloid leukemia remains unacceptably low, in large
part owing to resistance to chemotherapy and high rates of relapse. There is an urgent need …

There is a need to discover and develop non-toxic antibiotics that are effective against
metabolically dormant bacteria, which underlie chronic infections and promote antibiotic …

Multiple sclerosis (MS) is a neurodegenerative, autoimmune disease that is still incurable.
Nowadays, a variety of new drugs are being developed to prevent excessive inflammation …

Summary The ClpC1: ClpP1P2 protease is a core component of the proteostasis system in
mycobacteria. To improve the efficacy of antitubercular agents targeting the Clp protease …

The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has demonstrated promising efficacy in a
variety of hematologic malignancies. However, the precise mechanism of action of the drug …